These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1526678)

  • 21. In vivo activity of cefodizime.
    Shah PM; Knothe H
    Infection; 1992; 20 Suppl 1():S9-13. PubMed ID: 1526686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Brogden RN
    Drugs; 1992 Nov; 44(5):800-34. PubMed ID: 1280568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro antimicrobial activity of cefodizime, a third generation cephalosporin.
    Pruksachatvuthi S; Aswapokee N; Aswapokee P
    J Med Assoc Thai; 1992 May; 75(5):287-92. PubMed ID: 1460409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of cefodizime on chemotaxis and the respiratory burst in neutrophils from diabetics.
    Shaio MF; Chang FY
    J Antimicrob Chemother; 1990 Jul; 26(1):55-9. PubMed ID: 2211447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cefodizime on peritoneal mononuclear- and polymorphonuclear-cell chemotaxis.
    Ustün H; Ersoy FF; Sezer T; Ozcan S; Bozcuk H; Yegin O; Balci M; Süleymanlar G; Yakupoglu G
    Adv Perit Dial; 1998; 14():154-7. PubMed ID: 10649715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefodizime, an aminothiazolyl cephalosporin. III. Therapeutic activity against experimentally induced pneumonia in mice.
    Klesel N; Limbert M; Seibert G; Winkler I; Schrinner E
    J Antibiot (Tokyo); 1984 Dec; 37(12):1712-8. PubMed ID: 6098572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers.
    Bryskier A; Procyk T; Tremblay D; Lenfant B; Fourtillan JB
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():65-70. PubMed ID: 2074253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological effects of cefodizime in patients undergoing antineoplastic chemotherapy.
    Mallmann P; Brühl P
    Infection; 1992; 20 Suppl 1():S67-70. PubMed ID: 1526683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental evaluation of antibiotics as immunomodulators].
    Labro MT
    J Chemother; 1994 Aug; 6 Suppl 3():11-5. PubMed ID: 7861202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
    Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
    Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bactericidal activity of cefodizime on Enterobacteriaceae in an in-vitro model simulating plasma pharmacokinetics in humans.
    Péchinot A; Neuwirth C; Bryskier A; Duez JM; Kazmierczak A
    J Antimicrob Chemother; 1997 Feb; 39(2):157-62. PubMed ID: 9069535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefodizime, an aminothiazolylcephalosporin. V. Synthesis and structure-activity relationships in the cefodizime series.
    Blumbach J; Dürckheimer W; Ehlers E; Fleischmann K; Klesel N; Limbert M; Mencke B; Reden J; Scheunemann KH; Schrinner E
    J Antibiot (Tokyo); 1987 Jan; 40(1):29-42. PubMed ID: 3558116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immune response to antibiotics in patients with secondary immunodeficiencies].
    Meroni PL
    J Chemother; 1994 Aug; 6 Suppl 3():16-8. PubMed ID: 7861203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo enhancement of bactericidal activity of phagocytes against Klebsiella pneumoniae treated with subminimal inhibitory concentrations of cefodizime.
    Nomura S; Nagayama A
    Chemotherapy; 1995; 41(3):178-86. PubMed ID: 7656663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial agents as biological response modifiers (BRM) and chrono-immunomodulation: an emerging relationship.
    Dammacco F; Halberg F; Carandente F
    Chronobiologia; 1988; 15(1-2):25-39. PubMed ID: 3046851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of cefodizime on the immune system: in vitro studies].
    Limbert M
    Immun Infekt; 1986 Feb; 14(1):28-9. PubMed ID: 3485562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose pharmacokinetics of cefodizime in critically ill elderly patients.
    Meyer B; Traunmueller F; Bojic A; Locker G; Schmid R; Winkler S; Thalhammer F
    Int J Antimicrob Agents; 2006 Apr; 27(4):335-8. PubMed ID: 16563704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of cefodizime: a review of the data on file.
    Barré J
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():95-101. PubMed ID: 2074258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decrease in surface charge density of Klebsiella pneumoniae treated with cefodizime and enhancement of the phagocytic function of human polymorphonuclear leucocytes stimulated by the drug-treated bacteria.
    Muratsugu M; Miyake Y; Ishida N; Hyodo A; Terayama K
    Biol Pharm Bull; 1995 Sep; 18(9):1259-63. PubMed ID: 8845818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.